Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.010.32%
QQQ
711.420.07%
BTC/USD
77626.226.3234%
DIA
530.480.56%
GLD
421.431.49%
TLT
82.110.27%

Prelude Therapeutics Inc

PRLDNASDAQ
Trade with Public
Trade with Public
$6.59
0.0951.46%
Last update: Aug 21, 10:47 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Prelude Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Prelude Therapeutics (PRLD).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

3S.Buy
2Buy
1Sell
Consensus RatingMarket Outperform# Analysts6Avg. Consensus PT$5Upside to Avg. PT-17.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 29, 2026HC Wainwright & Co.Robert BurnsMaintainedBuy$8
May 4, 2026D. Boral CapitalJason KolbertInitiateBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $8 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

D. Boral Capital analyst Jason Kolbert initiates coverage on Prelude Therapeutics (NASDAQ:PRLD) with a Buy rating and announces Price Target of $9.
Benzinga Newsdesk

Seagate To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Monday

Wall Street analysts changed their outlook on top companies. Truist Securities, Guggenheim, Benchmark, HC Wainwright, Stifel, B of A Sec, Mizuho updated their ratings and price targets.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $5 to $8.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and raises the price target from $3 to $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved